Skip to main content

Advertisement

SpringerLink
Log in

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [90Y-DOTA0,Tyr3]octreotide may result in partial remissions in 10–25% of patients. The newer analogue [DOTA0,Tyr3]octreotate (octreotate) has a ninefold higher affinity for the somatostatin receptor subtype 2 as compared with [DOTA0,Tyr3]octreotide. Also, labelled with the beta- and gamma-emitting radionuclide 177Lu, it has proved very successful in achieving tumour regression in animal models. The effects of 177Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3–6 months after receiving their final dose. Patients were treated with doses of 100, 150 or 200 mCi 177Lu-octreotate, to a final cumulative dose of 600–800 mCi, with treatment intervals of 6–9 weeks. Nausea and vomiting within the first 24 h after administration were present in 30% and 14% of the administrations, respectively. WHO toxicity grade 3 anaemia, leucocytopenia and thrombocytopenia occurred after 0%, 1% and 1% of the administrations, respectively. Serum creatinine and creatinine clearance did not change significantly. The effects of the therapy on tumour size were evaluable in 34 patients. Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period. Tumour response was positively correlated with a high uptake on the octreoscan, limited hepatic tumour mass and a high Karnofsky Performance Score. Because of the limited efficacy of alternative therapies, many physicians currently adopt an expectant attitude when dealing with patients with metastatic GEP tumours. However, in view of the high success rate of therapy with 177Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

References

  1. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 1993; 54 (Suppl 1):72–75.

    Google Scholar 

  2. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32:225–229.

    CAS  PubMed  Google Scholar 

  3. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276–3281.

    Article  CAS  PubMed  Google Scholar 

  4. Valkema R, de Jong M, Bakker WH, Breeman WAP, Kooij PPM, Lugtenburg PJ, de Jong FH, Christiansen A, Kam BLR, de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110–122.

    PubMed  Google Scholar 

  5. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94-102.

    CAS  PubMed  Google Scholar 

  6. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941–945.

    CAS  PubMed  Google Scholar 

  7. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426–434.

    CAS  PubMed  Google Scholar 

  8. Valkema R, Jamar F, Bakker WH, Norenberg J, Smith C, Stolz B, Kvols L, Pauwels S, Krenning EP. Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487;OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. Eur J Nucl Med 2001; 28:1025.

    Google Scholar 

  9. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.

    CAS  PubMed  Google Scholar 

  10. Erion JL, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model. J Nucl Med 1999; 40:223P.

    Google Scholar 

  11. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28:1319–1325.

    CAS  PubMed  Google Scholar 

  12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez A, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365–376.

    PubMed  Google Scholar 

  13. De Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0),Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628–633.

    PubMed  Google Scholar 

  14. De Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42:1841–1846.

    PubMed  Google Scholar 

  15. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WAP, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133–140.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank all supporting personnel of the Department of Nuclear Medicine for their expert help and effort.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    D. J. Kwekkeboom, W. H. Bakker, B. L. Kam, J. J. M. Teunissen, P. P. M. Kooij, M. de Jong & E. P. Krenning

  2. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

    W. W. de Herder, R. A. Feelders & E. P. Krenning

  3. Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands

    C. H. J. van Eijck

  4. Mallinckrodt Medical, St. Louis, Missouri, USA

    A. Srinivasan & J. L. Erion

Authors
  1. D. J. Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. H. Bakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. L. Kam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. J. M. Teunissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. P. M. Kooij
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. A. Feelders
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. H. J. van Eijck
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. L. Erion
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. J. Kwekkeboom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwekkeboom, D.J., Bakker, W.H., Kam, B.L. et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med 30, 417–422 (2003). https://doi.org/10.1007/s00259-002-1050-8

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-002-1050-8

Keywords

Search

Navigation